MB
BIOA

MPM BioImpact’s BioAge Labs BIOA Stock Holding History

MPM BioImpact’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9M Buy
+1,667,661
New +$30.1M 2.49% 17

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

MPM BioImpact's BIOA Position: Q2 2026 in Review

MPM BioImpact opened a new position in BioAge Labs (BIOA) in Q2 2026: 1,667,661 shares worth $40.9M. The stake represents 2.49% of the portfolio and ranks #17 among its holdings.

139 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • MPM BioImpact held 1,667,661 shares of BioAge Labs worth $40.9M as of Q2 2026.
  • BioAge Labs was a new MPM BioImpact position in Q2 2026.
  • BioAge Labs made up 2.49% of MPM BioImpact's portfolio in Q2 2026, its #17 holding.
  • 139 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.